GlobeNewswire Inc | Jan 6, 2022 04:05PM EST

January 06, 2022

BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (Gain),a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Chief Executive Officer Eric Richman, will participate in the H.C. Wainwright Bioconnect Conference and invites investors to participate via webcast. Please see additional details below:

H.C. Wainwright BioConnect Virtual ConferenceMonday, January 10^th - Wednesday, January 13^th Registration Link

A webcast will be available for 90 days on the Investor Relations section ofthe Gain Therapeutics website on January 10^th at 7am ET or by using thefollowing link:

Webcast Link

About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinsons Research (MJFF) and The Silverstein Foundation for Parkinsons with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.

For more information, visit https://www.gaintherapeutics.com/

Investor Contact:Daniel FerryLifeSci Advisors+1 617-430-7576daniel@lifesciadvisors.com